Early-stage preclinical research continues to dominate hantavirus vaccine efforts, with candidates such as mRNA platforms from UTMB and the Moderna-Korea University collaboration demonstrating protective immunity in rodent and hamster models as recently as mid-2026, yet remaining far from human trials or regulatory review. No FDA-approved vaccines or therapeutics exist, and standard development pathways require years of phased clinical testing, manufacturing scale-up, and safety data before any product could reach availability. Recent outbreaks, including the 2026 cruise-ship cluster, have not triggered emergency-use pathways sufficient to compress these timelines. Only an unforeseen acceleration—such as rapid initiation and completion of pivotal trials amid a major epidemic—could realistically alter the near-certain trader consensus against a 2026 outcome.